Home/ Supplements/ Phosphorus/ Virt-Phos 250 Neutral

Virt-Phos 250 Neutral

product on market Tablet or Pill Virtus Pharmaceuticals Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 100% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · grounded in 1 source · methodology

The ingredients consist of phosphate salts used primarily as buffering agents to maintain pH balance. Research evidence for these specific compounds in a supplemental context is limited. These components are generally recognized as safe for their intended use.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for Virt-Phos 250 Neutral
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Tablet(s)
Serving Size
Other Combinations
Product Type
100%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Market median: 4002.0mg (1 products) 21 studies (A:0, B:2)
Market median: 4002.0mg (1 products) 21 studies (A:0, B:2)
Market median: 4002.0mg (1 products) 21 studies (A:0, B:2)

Other Ingredients

Microcrystalline Cellulose Croscarmellose Sodium Stearic Acid Magnesium Stearate Silicon Dioxide
Claims

Label Claims — Verification

Unverified All Other
Info

Product Information

Directions for Use

Directions for use: Virt-Phos 250 Neutral should be taken with a full glass of water, with meal and at bedtime. Adults: One or two tablets four times daily; Pediatric patients over 4 years of age: One tablet four times daily; Pediatric under 4 years of age: Use only as directed by a licensed healthcare practitioner.

Warnings & Precautions

Allergy: Product may be exposed to tree nuts, peanuts, fish, egg, wheat, milk, soy, and shellfish during manufacture. See prescribing information.

Precautions, contraindications, side effects: See prescribing information.

Keep out of reach of children

Call your licensed medical practitioner about side effects. You may report side effects by calling Vitrus at 1-888-848-3593 or FDA at 1-800-FDA-1088.

Formulation Notes

Supplying 250 mg per tablet

Each tablet yields approximately 250 mg (25% DV for adults) of phosphorus. 298 mg sodium (13.0 mEq), and 45 mg of potassium (1.1 mEq).

Description: Virt-Phos 250 Neutral is a prescription phosphorus dietary supplement - supplying 250 mg per tablet for use in the dietary supplement of hypophosphatemia and should be administered under the supervision of a licensed medical practitioner.

Additional Information

69543-268-10

Rx Made in USA

Storage: Store at 20(0) to 25(0)C (68(0) to 77(0)F). Excursions permitted to 15(0) to 30(0)C (59(0) to 86(0)F). Protect from light and moisture. Dispense in a tight, light-resistant container. Notice: Contact with moisture may product surface discoloration or erosion.

Rev. 06/16

Metadata

Product Details

UPC / SKU3 69543 26810 1
DSLD Entry Date2018-09-21
Product TypeOther Combinations
FormTablet or Pill
DSLD ID180560
Data Updated2026-04-11
Research

Research Evidence

46
Research Sources
55
Avg Quality
23
Meta Analysis
7
Systematic Review
7
Rct
4
Clinical Trial
2
Other
1
Guideline
1
Regulatory Source
A Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
B Phosphate binders for preventing and treating bone disease in chronic kidney disease patients
Meta Analysis The Cochrane database of systematic reviews 2011 PubMed DOI
B Calcium and phosphorus supplementation of human milk for preterm infants
Systematic Review The Cochrane database of systematic reviews 2017 PubMed DOI
B Radiographic and clinical outcomes of silicate-substituted calcium phosphate (SiCaP) bone grafts in spinal fusion: Systematic review and meta-analysis
Meta Analysis Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2020 PubMed DOI
B ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Calcium, phosphorus and magnesium.
Guideline Clinical nutrition (Edinburgh, Scotland) 2018 PubMed DOI
B Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials
Meta Analysis Annals of palliative medicine 2022 PubMed DOI
B Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia
Meta Analysis The Cochrane database of systematic reviews 2015 PubMed DOI
B The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials
Meta Analysis Journal of nephrology 2022 PubMed DOI
B Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies
Meta Analysis Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2024 PubMed DOI
View all evidence for Phosphorus →
Compare

Similar Products

View all Phosphorus products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.